Shoulder FracturesNCT04984291
Zimmer Biomet Shoulder Arthroplasty PMCF
A study testing Alliance Glenoid and Identity Stem in people with Shoulder Fractures and Shoulder Arthritis, run by Zimmer Biomet at 17 sites in 3 countries.
Trial summary
The objectives of this study are to confirm the safety, performance, and clinical benefits of Zimmer Biomet Shoulder Arthroplasty Systems and its instrumentation in primary or revision shoulder arthroplasty. Read more about this study
- Who is it for?
- Ages 20 years and older
- Conditions the study is for
- Shoulder Fractures, Shoulder Arthritis, Shoulder Osteoarthritis
- What is being tested?
- Alliance Glenoid and Identity Stem
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 584 participants
- Where
- 17 sitesin 3 countries
- Study dates
- 28 Jul 2021to 15 Aug 2033
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patient must be 20 years of age or older.
- Patient must be anatomically and structurally suited to receive shoulder arthroplasty implants.
- Patient is a candidate for shoulder arthroplasty due to one or more of the following:
- Non-inflammatory degenerative joint disease including osteoarthritis and avascular necrosis.
- Rheumatoid arthritis.
- Correction of functional deformity.
Show all 14Show fewer
- Fractures of the proximal humerus, where other methods of treatment are deemed inadequate.
- Difficult clinical management problems, where other methods of treatment may not be suitable or may be inadequate.
- Patient must be able and willing to complete the protocol required follow-up.
- Patient must be able and willing to sign the IRB/EC approved informed consent.
- Patient has grossly deficient rotator, (for reverse application)
- With severe arthropathy and/or
- Previously failed shoulder joint replacement
- Patient must have functional deltoid muscle (for reverse application)
Who cannot join
- Patient is unwilling or unable to give consent or to comply with the follow-up program.
- Patient has any condition which would in the judgement of the Investigator, place the patient at undue risk or interfere with the study.
- Patient is known to be pregnant or breastfeeding.
- Patient is a vulnerable subject (prisoner, mentally incompetent or unable to understand what participation to the study entails, a known alcohol or drug abuser, and/or anticipated to be non-compliant).
- Patient is uncooperative or patient with neurologic disorders who is incapable or unwilling to follow directions.
- Patient has any sign of infection affecting the shoulder joint or in its proximity which may spread to the implant site.
Show all 15Show fewer
- Patient has rapid joint destruction, marked bone loss, or bone resorption apparent on roentgenogram.
- Patient has any neuromuscular disease compromising the affected limb that would render the procedure unjustifiable.
- Patient presents with osteoporosis, which in the opinion of the Investigator, may limit the subject's ability to support total shoulder arthroplasty using the study device.
- Patient has osteomalacia.
- Patient has a metabolic disorder that may impair bone formation.
- Patient has deficient rotator cuff.
- Patient presents with significant injury to the upper brachial plexus.
- Patient has paralysis of the axillary nerve.
- Patient has non-functional deltoid or external rotator muscles.
Trial locations and contacts
17 sites in 3 countries. Contact the study team or a site near you to ask about taking part.
Ryan Boylan, MBA contact
17 sites in 3 countries
United States12 sites, 2 recruiting
- Active, not recruiting
TRIA Orthopaedic Center Research Institute
Bloomington, Minnesota, 55431
- Active, not recruiting
University of Buffalo
Buffalo, New York, 14215
- Active, not recruiting
Northwestern University
Chicago, Illinois, 60208
- Active, not recruiting
Advance Bone and Joint
City of Saint Peters, Missouri, 63376
- Recruiting
Panorama Orthopaedic and Spine Center
Golden, Colorado, 80401
Paul Lee, PA, 720-497-6697, ResearchCoordinators@panoramaortho.com
ResearchCoordinators@panoramaortho.com
- Active, not recruiting
Hoag Orthopedic Institute
Irvine, California, 92618
- Active, not recruiting
Mississippi Sports Medicine and Orthopaedic Center, PLLC
Jackson, Mississippi, 39202
- Terminated
Norton Healthcare, Inc
Louisville, Kentucky, 40202
- Recruiting
Intermountain Health
Murray, Utah, 84107
Maha Maleki, BS, 801-507-8095, Maha.Maleki@imail.org
Matt Schneider, MS, 801-507-8095, Matthew.Schneider@imail.org
- Active, not recruiting
Rothman Institute
Philadelphia, Pennsylvania, 19107
- Active, not recruiting
William Beaumont Hospital
Royal Oak, Michigan, 48073
- Active, not recruiting
Washington University
St Louis, Missouri, 63130
Japan4 sites
- Active, not recruiting
Fukui General Hospital
Fukui, 910-3113
- Active, not recruiting
Iwaki City Medical Center
Fukushima, 973-8555
- Active, not recruiting
Yuuai Medical Center
Okinawa, 901-0224
- Withdrawn
Kichijoji Minami Hospital
Tokyo, 180-0003
About this study
Official title: Zimmer Biomet Shoulder Arthroplasty Long-term Post Market Clinical Follow-up Study
The objectives of this study are to confirm the safety, performance, and clinical benefits of Zimmer Biomet Shoulder Arthroplasty Systems and its instrumentation in primary or revision shoulder arthroplasty. These objectives will be assessed using standard scoring systems, radiographic evidence, and adverse event records. Safety of the system will be assessed by monitoring the frequency an incidence of adverse events.
Read the detailed description
The primary endpoint is defined as survival of the implant at 10 years, which is based on removal or intended removal of at least 1-study implant component and will be determined by using the Kaplan Meier method. The safety of the system will be assessed by monitoring the frequency and incidence of adverse events. Separate analysis will be done for each arm of the study.
The secondary endpoint is represented by the performance and clinical benefits of Zimmer Biomet Shoulder Arthroplasty Systems and its instrumentation after 2 years, which will be assessed by the American Shoulder and Elbow Surgeons (ASES) shoulder score. The secondary endpoint evaluation will also assess the overall pain, functional performance, quality of life and radiographic parameters of all enrolled study subjects.
- Conditions
- Shoulder Fractures, Shoulder Arthritis, Shoulder Osteoarthritis, Shoulder Deformity, Shoulder Injuries, Shoulder Pain
- Being tested
- Alliance Glenoid, Identity Stem
- Keywords
- Total Shoulder Arthroplasty, Glenoid, Humeral Stem, Stem Adapter, Humeral Head, Humeral Bearing, Humeral Trays, Head Adapter, Reverse, Anatomic, Hemi
- Medical subject headings
- Shoulder Fractures, Shoulder Injuries, Shoulder Pain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Alliance GlenoidDevice
Also called Alliance
Alliance Glenoid used in Primary or Revision Total Shoulder Arthroplasty
Identity StemDevice
Also called Identity
Identity Shoulder System is intended to be used in anatomic total shoulder arthroplasty, shoulder hemi-arthroplasty, or total reverse shoulder arthroplasty in both Primary or Revision Total Shoulder Arthroplasty
| Study group | Role | What they receive |
|---|---|---|
| Zimmer Biomet Total Shoulder Arthroplasty System | Experimental | Patients who are having primary or revision total shoulder arthroplasty who will receive a Zimmer Biomet Total Shoulder Arthroplasty System. Receives: Device: Alliance Glenoid; Device: Identity Stem |
What is being measured
The primary outcome is the main question the study is designed to answer.
Implant Survivorship at 10 years follow-up (Kaplan Meier)
Based on removal or intended removal of the device and determined using the Kaplan-Meier method.
Measured: 10 years
Frequency and Incidence of Adverse Events (Safety)
Monitoring the frequency and incidence of adverse events, serious adverse events, adverse device effects, serious adverse device effects, and unanticipated serious adverse device effects as well as device deficiencies.
Measured: 10 years
Secondary outcomes (7)
Clinical efficacy of the device is assessed using the American Shoulder and Elbow Surgeons (ASES) Shoulder Score at 2 years follow-up
Pain, function, and activities of daily living are measured. The ASES scale is 0-100. 100 is the highest score and indicates the greatest function while 0 is the lowest score.
Measured: 2 years
Euroqol Patient Quality of life measured at 2 years follow-up (EQ-5D-5L)
The EuroQol five dimensions questionnaire (EQ-5D-5L) is a five dimensional self-assessment that is comprised of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. These five dimensions can be used to index a subject's health utility on a scale of 0 to 1, where 0 is death and 1 is perfect health. The scoring rule for EQ-5D permits scores less than 0, implying that some health states may be worse than death.
Measured: 2 years
Radiographic Performance [Radiolucency] at 2 years follow-up
X-rays will be evaluated for radiolucency lines to show the number of subjects with radiolucency. Radiolucency refers to structures that are less dense and permit the x-ray beam to pass through them. Radiolucent structures appear dark or black in the radiographic image.
Measured: 2 years
Radiographic Performance [Osteolysis] at 2 years follow-up
X-rays will be evaluated for osteolysis to show the number of subjects with osteolysis. Osteolysis is a progressive condition where bone tissue is destroyed. In this process, bones lose minerals (mostly calcium), softens, degenerates and become weaker.
Measured: 2 years
Radiographic Performance [Heterotopic Ossification] at 2 years follow-up
X-rays will be evaluated for heterotopic ossification to show the number of subjects with heterotopic ossification. Heterotopic ossification refers to the presence of bone in soft tissue where bone normally does not exist (extraskeletal bone).
Measured: 2 years
Radiographic Performance [Humeral Component Subsidence] at 2 years follow-up
X-rays will be evaluated for humeral component subsidence to show the number of subjects with subsidence. Component Subsidence refers to the presence of the device component gradually sinking or caving into the bone structure.
Measured: 2 year
Radiographic Performance [Glenoid Component Migration] at 2 years follow-up
X-rays will be evaluated for glenoid component migration to show the number of subjects with migration. Component migration refers to the presence of the device component gradually moving anteriorly, posteriorly, superiorly, or inferiorly in relation to original placement.
Measured: 2 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Jul 2021
- Study start28 Jul 2021
- Primary completion15 Aug 2033 (estimated)
- Study completion15 Aug 2033 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Shoulder FracturesStudies of the same condition, open and under way.
- More trials run by Zimmer BiometThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 584 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Zimmer Biomet
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Ryan Boylan, Study director, Zimmer Biomet
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04984291
- Sponsor's protocol ID
- CMU2019-35E
- Status last verified
- Apr 2026
- First submitted
- 16 Jul 2021
- Last updated
- 28 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 28 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Zimmer Biomet Shoulder Arthroplasty Long-term Post Market Clinical Follow-up Study
- ClinicalTrials.gov ID
- NCT04984291
- Acronym / sponsor ID
- CMU2019-35E
- Conditions
- Shoulder Fractures, Shoulder Arthritis, Shoulder Osteoarthritis, Shoulder Deformity, Shoulder Injuries, Shoulder Pain
- Keywords
- Total Shoulder Arthroplasty, Glenoid, Humeral Stem, Stem Adapter, Humeral Head, Humeral Bearing, Humeral Trays, Head Adapter
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 584 participants (estimated)
- Lead sponsor
- Zimmer BiometIndustry (pharma, biotech, devices)
- Study start
- 28 Jul 2021 (actual)
- Primary completion
- 15 Aug 2033 (estimated)
- Study completion
- 15 Aug 2033 (estimated)
- First posted
- 30 Jul 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objectives of this study are to confirm the safety, performance, and clinical benefits of Zimmer Biomet Shoulder Arthroplasty Systems and its instrumentation in primary or revision shoulder arthroplasty. These objectives will be assessed using standard scoring systems, radiographic evidence, and adverse event records. Safety of the system will be assessed by monitoring the frequency an incidence of adverse events.
Detailed description
The primary endpoint is defined as survival of the implant at 10 years, which is based on removal or intended removal of at least 1-study implant component and will be determined by using the Kaplan Meier method. The safety of the system will be assessed by monitoring the frequency and incidence of adverse events. Separate analysis will be done for each arm of the study.
The secondary endpoint is represented by the performance and clinical benefits of Zimmer Biomet Shoulder Arthroplasty Systems and its instrumentation after 2 years, which will be assessed by the American Shoulder and Elbow Surgeons (ASES) shoulder score. The secondary endpoint evaluation will also assess the overall pain, functional performance, quality of life and radiographic parameters of all enrolled study subjects.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Zimmer Biomet Total Shoulder Arthroplasty System | Experimental | Device: Alliance Glenoid, Device: Identity StemPatients who are having primary or revision total shoulder arthroplasty who will receive a Zimmer Biomet Total Shoulder Arthroplasty System. |
Who may qualify
- Ages
- 20 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (14 listed)
- Patient must be 20 years of age or older.
- Patient must be anatomically and structurally suited to receive shoulder arthroplasty implants.
- Patient is a candidate for shoulder arthroplasty due to one or more of the following:
- Patient must be able and willing to complete the protocol required follow-up.
- Patient must be able and willing to sign the IRB/EC approved informed consent.
Key exclusion criteria (15 listed)
- Patient is unwilling or unable to give consent or to comply with the follow-up program.
- Patient has any condition which would in the judgement of the Investigator, place the patient at undue risk or interfere with the study.
- Patient is known to be pregnant or breastfeeding.
- Patient is a vulnerable subject (prisoner, mentally incompetent or unable to understand what participation to the study entails, a known alcohol or drug abuser, and/or anticipated to be non-compliant).
- Patient is uncooperative or patient with neurologic disorders who is incapable or unwilling to follow directions.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Alliance GlenoidAlso: AllianceAlliance Glenoid used in Primary or Revision Total Shoulder Arthroplasty | Device | Zimmer Biomet Total Shoulder Arthroplasty System |
| Identity StemAlso: IdentityIdentity Shoulder System is intended to be used in anatomic total shoulder arthroplasty, shoulder hemi-arthroplasty, or total reverse shoulder arthroplasty in both Primary or Revision Total Shoulder Arthroplasty | Device | Zimmer Biomet Total Shoulder Arthroplasty System |
Primary outcome
Implant Survivorship at 10 years follow-up (Kaplan Meier)
Time frame: 10 years
Based on removal or intended removal of the device and determined using the Kaplan-Meier method.
Frequency and Incidence of Adverse Events (Safety)
Time frame: 10 years
Monitoring the frequency and incidence of adverse events, serious adverse events, adverse device effects, serious adverse device effects, and unanticipated serious adverse device effects as well as device deficiencies.
7 secondary outcomes
Clinical efficacy of the device is assessed using the American Shoulder and Elbow Surgeons (ASES) Shoulder Score at 2 years follow-up
Time frame: 2 years
Euroqol Patient Quality of life measured at 2 years follow-up (EQ-5D-5L)
Time frame: 2 years
Radiographic Performance [Radiolucency] at 2 years follow-up
Time frame: 2 years
Radiographic Performance [Osteolysis] at 2 years follow-up
Time frame: 2 years
Radiographic Performance [Heterotopic Ossification] at 2 years follow-up
Time frame: 2 years
Radiographic Performance [Humeral Component Subsidence] at 2 years follow-up
Time frame: 2 year
Radiographic Performance [Glenoid Component Migration] at 2 years follow-up
Time frame: 2 year
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Apr 2026.
Related trials for Shoulder Fractures
RecruitingObservational study
Duration of Immobilization After Reverse Total Arthroplasty for Proximal Humerus Fractures
Proximal Humeral Fracture, Reverse Total Shoulder Arthroplasty
Recruiting
SMR Stemless Reverse vs SMR Reverse Shoulder System
Arthroplasty, Replacement
Active, not recruitingObservational study
Outcomes of Arthroscopic Dynamic Anterior Stabilization With and Without Remplissage
Anterior Shoulder Instability
Not yet recruiting
Study on Outcomes of Proximal Humerus Fractures
Proximal Humerus Fracture
Recruiting
Comparison of Surgical Techniques for Anterior Shoulder Instability
Surgeons, Shoulder Instability
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Ryan Boylan, MBA contact
Ryan Boylan study director
Zimmer Biomet
17 sites in 3 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Alliance Glenoid and Identity Stem in people with Shoulder Fractures and Shoulder Arthritis, run by Zimmer Biomet at 17 sites in 3 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 14 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 28 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 17 sites in United States, Japan, New Zealand. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Cayla Lafollette, BS (574 268-8610, Cayla.lafollette@zimmerbiomet.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Implant Survivorship at 10 years follow-up (Kaplan Meier) (time frame: 10 years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Apr 2026.